Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment

British Journal of Pharmacology

Volumn 165, Issue 5, 2012, Pages 1424-1441

  Abassi, Yama A ^a,b   Xi, Biao ^a   Li, Nan ^a   Ouyang, Wei ^a   Seiler, Alexander ^c   Watzele, Manfred ^c   Kettenhofen, Ralf ^d   Bohlen, Heribert ^d   Ehlich, Andreas ^d   Kolossov, Eugen ^d   Wang, Xiaobo ^a   Xu, Xiao ^a,b  

^a ACEA Biosciences Inc   (United States)

^b Hangzhou High Throughput Screening Center   (China)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d Pluriomics BV   (Germany)

Author keywords

cardio safety; cardiomyocyte; cardiotoxicity; hERG; ion channel; label free; mechanistic toxicology; predictive assay; safety pharmacology; stem cell

Indexed keywords

CALCIUM CHANNEL; DOXORUBICIN; ION CHANNEL; IONOTROPIC RECEPTOR AGONIST; MOXIFLOXACIN; MYOSIN HEAVY CHAIN ALPHA; PENTAMIDINE; POTASSIUM CHANNEL; SODIUM CHANNEL; VOLTAGE GATED CALCIUM CHANNEL;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CARDIOTOXICITY; CARDIOVASCULAR RESPONSE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DRUG SAFETY; GENE EXPRESSION; HEART ARRHYTHMIA; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMPEDANCE; MEASUREMENT; MICROELECTRONIC DETECTION SYSTEM; MONITORING; MOUSE; NONHUMAN; PERIODICITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; STEM CELL; TRANSGENE;

ANIMALS; CALCIUM CHANNELS; CELLS, CULTURED; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ELECTRIC IMPEDANCE; EMBRYONIC STEM CELLS; ETHER-A-GO-GO POTASSIUM CHANNELS; MICE; MYOCYTES, CARDIAC; POTASSIUM CHANNELS; SODIUM CHANNELS; TORSADES DE POINTES;

EID: 84863116827     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01623.x     Document Type: Article

References (60)

1. Abassi YA, Xi B, Zhang W, Ye P, Kirstein SL, Gaylord MR, et al,. (2009). Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem Biol 16: 712-723.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Arrigoni C, Crivori P, (2007). Assessment of QT liabilities in drug development. Cell Biol Toxicol 23: 1-13.
4. Atienza JM, Yu N, Kirstein SL, Xi B, Wang X, Xu X, et al,. (2006a). Dynamic and label-free cell-based assays using the real-time cell electronic sensing system. Assay Drug Dev Technol 4: 597-607.
5. Atienza JM, Yu N, Wang X, Xu X, Abassi Y, (2006b). Label-free and real-time cell-based kinase assay for screening selective and potent receptor tyrosine kinase inhibitors using microelectronic sensor array. J Biomol Screen 11: 634-643.
6. Balasubramanian B, Imredy JP, Kim D, Penniman J, Lagrutta A, Salata JJ, (2009). Optimization of Ca(v)1.2 screening with an automated planar patch clamp platform. J Pharmacol Toxicol Methods 59: 62-72.
7. Bers DM, (2002). Cardiac excitation-contraction coupling. Nature 415: 198-205.
8. Bosch RF, Gaspo R, Busch AE, Lang HJ, Li GR, Nattel S, (1998). Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc Res 38: 441-450.
9. Bouchard RA, Clark RB, Giles WR, (1995). Effects of action potential duration on excitation-contraction coupling in rat ventricular myocytes. Action potential voltage-clamp measurements. Circ Res 76: 790-801.
10. Brown AM, (2005). HERG block, QT liability and sudden cardiac death. Novartis Found Symp 266: 118-131. Discussion 131-115, 155-118.
11. Denning C, Anderson D, (2008). Cardiomyocytes from human embryonic stem cells as predictors of cardiotoxicity. Drug Discovery Today 5: 223-232.
12. Dennis A, Wang L, Wan X, Ficker E, (2007). hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 35: 1060-1063.
13. Doetschman TC, Eistetter H, Katz M, Schmidt W, Kemler R, (1985). The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J Embryol Exp Morphol 87: 27-45.
14. Dou Y, Arlock P, Arner A, (2007). Blebbistatin specifically inhibits actin-myosin interaction in mouse cardiac muscle. Am J Physiol Cell Physiol 293: C1148-C1153.
15. Fedorov VV, Lozinsky IT, Sosunov EA, Anyukhovsky EP, Rosen MR, Balke CW, et al,. (2007). Application of blebbistatin as an excitation-contraction uncoupler for electrophysiologic study of rat and rabbit hearts. Heart Rhythm 4: 619-626.
16. Fermini B, Fossa AA, (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2: 439-447.
17. Fijnvandraat AC, van Ginneken AC, de Boer PA, Ruijter JM, Christoffels VM, Moorman AF, et al,. (2003). Cardiomyocytes derived from embryonic stem cells resemble cardiomyocytes of the embryonic heart tube. Cardiovasc Res 58: 399-409.
18. Force T, Kolaja KL, (2011). Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov 10: 111-126.
19. Franckowiak G, Bechem M, Schramm M, Thomas G, (1985). The optical isomers of the 1,4-dihydropyridine BAY K 8644 show opposite effects on Ca channels. Eur J Pharmacol 114: 223-226.
20. Freund C, Mummery CL, (2009). Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models. J Cell Biochem 107: 592-599.
21. Fujisawa S, Ono K, Iijima T, (2000). Time-dependent block of the slowly activating delayed rectifier K(+) current by chromanol 293B in guinea-pig ventricular cells. Br J Pharmacol 129: 1007-1013.
22. Gintant G, (2011). An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 129: 109-119.
23. Gintant GA, Su Z, Martin RL, Cox BF, (2006). Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. Toxicol Pathol 34: 81-90.
24. Gintant GA, Gallacher DJ, Pugsley MK, (2011). Commentary: the 'Overly-sensitive' heart: sodium channel block and QRS interval prolongation. Br J Pharmacol 164: 254-259.
25. Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, et al,. (2011). Somatic coding mutations in human induced pluripotent stem cells. Nature 471: 63-67.
26. Guth BD, Rast G, (2010). Dealing with hERG liabilities early: diverse approaches to an important goal in drug development. Br J Pharmacol 159: 22-24.
27. Halbach M, Egert U, Hescheler J, Banach K, (2003). Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell Physiol Biochem 13: 271-284.
28. van der Heyden MA, Smits ME, Vos MA, (2008). Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br J Pharmacol 153: 406-409.
29. Kamp TJ, Lyons GE, (2009). On the road to iPS cell cardiovascular applications. Circ Res 105: 617-619.
30. Kettenhofen R, Bohlen H, (2008). Preclinical assessment of cardiac toxicity. Drug Discovery Today 13: 702-707.
31. Kirstein SL, Atienza JM, Xi B, Zhu J, Yu N, Wang X, et al,. (2006). Live cell quality control and utility of real-time cell electronic sensing for assay development. Assay Drug Dev Technol 4: 545-553.
32. Kolossov E, Lu Z, Drobinskaya I, Gassanov N, Duan Y, Sauer H, et al,. (2005). Identification and characterization of embryonic stem cell-derived pacemaker and atrial cardiomyocytes. FASEB J 19: 577-579.
33. Kolossov E, Bostani T, Roell W, Breitbach M, Pillekamp F, Nygren JM, et al,. (2006). Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. J Exp Med 203: 2315-2327.
34. Kovacs M, Toth J, Hetenyi C, Malnasi-Csizmadia A, Sellers JR, (2004). Mechanism of blebbistatin inhibition of myosin II. J Biol Chem 279: 35557-35563.
35. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, et al,. (2005). Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312: 316-323.
36. Lacerda AE, Kuryshev YA, Chen Y, Renganathan M, Eng H, Danthi SJ, et al,. (2008). Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther 324: 427-433.
37. Maltsev VA, Ji GJ, Wobus AM, Fleischmann BK, Hescheler J, (1999). Establishment of beta-adrenergic modulation of L-type Ca2+ current in the early stages of cardiomyocyte development. Circ Res 84: 136-145.
38. Mandenius CF, Steel D, Noor F, Meyer T, Heinzle E, Asp J, et al,. (2011). Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review. J Appl Toxicol 31: 191-205.
39. Mellemkjaer S, Bang L, Nielsen-Kudsk F, (1992). Isradipine dynamics and pharmacokinetics in the isolated rabbit heart. Pharmacol Toxicol 70: 366-372.
40. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
41. Mitchell GF, Jeron A, Koren G, (1998). Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol 274: H747-H751.
42. Narahashi T, (2008). Tetrodotoxin: a brief history. Proc Jpn Acad Ser B Phys Biol Sci 84: 147-154.
43. Ono K, Shibata S, Iijima T, (2000). Properties of the delayed rectifier potassium current in porcine sino-atrial node cells. J Physiol 524: 51-62.
44. Peng S, Lacerda AE, Kirsch GE, Brown AM, Bruening-Wright A, (2010). The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J Pharmacol Toxicol Methods 61: 277-286.
45. Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, Valentin JP, (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159: 12-21.
46. Pouton CW, Haynes JM, (2007). Embryonic stem cells as a source of models for drug discovery. Nat Rev Drug Discov 6: 605-616.
47. Rapila R, Korhonen T, Tavi P, (2008). Excitation-contraction coupling of the mouse embryonic cardiomyocyte. J Gen Physiol 132: 397-405.
48. Roden DM, (2004). Drug-induced prolongation of the QT interval. N Engl J Med 350: 1013-1022.
49. Rubart M, Zipes DP, (2005). Mechanisms of sudden cardiac death. J Clin Invest 115: 2305-2315.
50. Sachinidis A, Fleischmann BK, Kolossov E, Wartenberg M, Sauer H, Hescheler J, (2003). Cardiac specific differentiation of mouse embryonic stem cells. Cardiovasc Res 58: 278-291.
51. Schramm M, Towart R, Kazda S, Thomas G, Franckowiak G, (1985). Calcium agonism, a new mechanism for positive inotropy. Hemodynamic effects and mode of action of BAY K 8644. Adv Myocardiol 6: 59-70.
52. Shah RR, (2005). Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf 28: 115-125.
53. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V, (2009). Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61: 154-171.
54. Singal PK, Iliskovic N, (1998). Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905.
55. Su Z, Widomski DL, Liu X, Limberis JT, Green J, Diaz G, et al,. (2010). A novel secretagogue increases cardiac contractility by enhancement of L-type Ca2+ current. Biochem Pharmacol 80: 1000-1006.
56. Triggle DJ, (2003). 1,4-Dihydropyridines as calcium channel ligands and privileged structures. Cell Mol Neurobiol 23: 293-303.
57. Valentin JP, (2010). Reducing QT liability and proarrhythmic risk in drug discovery and development. Br J Pharmacol 159: 5-11.
58. Volders PG, Stengl M, van Opstal JM, Gerlach U, Spatjens RL, Beekman JD, et al,. (2003). Probing the contribution of IKs to canine ventricular repolarization: key role for beta-adrenergic receptor stimulation. Circulation 107: 2753-2760.
59. Xi B, Yu N, Wang X, Xu X, Abassi YA, (2008). The application of cell-based label-free technology in drug discovery. Biotechnol J 3: 484-495.
60. Zahradnikova A, Minarovic I, Zahradnik I, (2007). Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther 322: 638-645.